Best Biotech Stocks To Invest In Right Now

The health care sector was in trouble over the past year, coming under fire from congressional hearings and politicians on the campaign trail. At first 2017 seemed like it could be different for this sector, but after President-elect Trumps recent comments that this industry was getting away with murder, the future is uncertain. In Thursdays trading session health care stocks were somewhat muted, but a few bucked this trend.

24/7 Wall St. has picked out some of the biggest moves in the sector that stood out from the rest on Thursday. We have included information about each company, as well as recent trading activity and the consensus price target.

Cellect Biotechnology Ltd. (NASDAQ: APOP) reported that it received a formal notice from the U.S. Patent and Trademark Office (USPTO)regarding its method of treatment for immune related disorders. Basically, the USPTO gave a notice of allowance which broadly means the agency intends to issue a patent approval. The treatment method relates to the engineering of regulatory immune cells with enhanced apoptotic activity used for the treatment or prevention for the unmet needs seen in type 1 diabetes, inflammatory bowel disease, graft versus host disease, and transplant rejection.

Best Biotech Stocks To Invest In Right Now: CVD Equipment Corporation(CVV)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Under the Radar Moversnewsletter suggested small cap materials and coatings stock CVD Equipment Corporation (NASDAQ: CVV) as a short/bearish trade:

  • [By Jim Robertson]

    At the beginning of the week, our Under the Radar Moversnewsletter suggestedsmall cap industrial machinery stock CVD Equipment Corporation (NASDAQ: CVV) as a long/bullish trade:

Best Biotech Stocks To Invest In Right Now: Starbucks Corporation(SBUX)

Advisors’ Opinion:

  • [By Chris Lange]

    Starbucks Corp. (NASDAQ: SBUX) released fiscal first-quarter financial results after markets closed Thursday. The company said that it had $0.65 in earnings per share (EPS) and $6.1 billion in revenue, compared with consensus estimates from Thomson Reuters that called for $0.57 in EPS and $6.18 billion in revenue. The same period from last year had $0.52 in EPS and $5.73 billion in revenue.

  • [By Ben Levisohn]

    Keurigs plight (actually, JABs) is worsening, with the K-cup market slowing to almost no growth now, and Keurig continuing to lose own brands share. Starbucks (SBUX) echoed the notion of a K-cup market slowdown at its seminar on Wednesday (and is guiding for its [consumer packaged goods, or CPG,] growth below recent trends), but it expects to increase its share of total CPG coffee to 20% from 15%. Come early February it will be a year since the closing of the Keurig deal for JAB Holdings. The pressure on JAB is more significant if we take into account the high leverage of the deal (JAB contributed one fourth of the $12Bn price tag). It is a tough predicament. On the one hand we argue that to make that deal work, they need to buy more (own) brands either from the retail channel (that can be extended to CPG: Dunkin (DNKN)? Panera (PNRA)?), or outright buy CPG brands (like the entire Kraft Heinz portfolio, and or Tata Groups Eight OClock brand). But can/how do they fund these deals? Maybe Mars and Warren Buffett (Mars is involved in office coffee with Starbucks), private equity, and or 3G can help? While this note is not about Positive-rated Mondelez, we have mentioned before a scenario where Kraft Heinz buys Mondelez and partly funds the deal by selling its own CPG coffee business (~$3Bn we say) to JAB as well as divests the Mondelez 20% plus stakes in Keurig (North America) and Jacobs Douwe Egberts (Western Europe), which together at this stage are worth ~$7-8Bn. But, yes, JAB will need deep-pocket partners and generous lenders. Net, JAB needs to do something soon.

  • [By ]

    Whatever the reason, cards have become the universally preferred payment method. Morning coffee at Starbucks (Nasdaq: SBUX). Swipe. Groceries on the way home from work. Swipe again. Heck, even taxi drivers and stadium hot dog vendors now carry portable card readers.

  • [By ]

    Shares of Starbucks Corp. (SBUX) were up nearly 2% in after-hours trading on Thursday, April 26, after the coffee chain reported a 2% rise in same-store sales in the fiscal second quarter, a better figure than expected, Morningstar Inc. analyst R.J. Hottovy said.

  • [By Chris Dier-Scalise]

    The IMX report also highlighted a sell-off among their clients in companies that experienced some friction during the month. Caterpillar Inc. (NYSE: CAT) was net sold as federal investigators continued their probe into the construction equipment company's export filings. Starbucks Corporation (NASDAQ: SBUX) was net sold as former CEO Howard Schultz prepared for his departure from the company in April.

Best Biotech Stocks To Invest In Right Now: Uni-Pixel, Inc.(UNXL)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Uni-Pixel (UNXL) manufactures electronic film products using its proprietary manufacturing process, UniBoss. This stock closed up 7.6% to $16.84 in Monday’s trading session.

    Monday’s Volume: 1.88 million

    Three-Month Average Volume: 1 million

    Volume % Change: 108%

    From a technical perspective, UNXL bounced sharply higher here right off its 50-day moving average of $15.89 with above-average volume. This stock looks to be forming a double bottom chart pattern at $14.91 to $15.16. If that bottom holds, then shares of UNXL could see a continuation of Monday’s upside action.

    Traders should now look for long-biased trades in UNXL as long as it’s trending above $15.16 or $14.91 and then once it sustains a move or close above Monday’s high of $17.53 with volume that hits near or above 1 million shares. If we get that move soon, then UNXL will set up to re-test or possibly take out its next major overhead resistance level at its 200-day moving average of $19.89.

  • [By Peter Graham]

    Small cap sensor film stockUniPixel Inc (NASDAQ: UNXL) reportedQ1 2017 earnings after the Thursday market close withshares falling both on Thursday and in afterhours trading. UniPixel is not well covered or known by analysts yet and this can make shares volatile. However and last September, we had suggested a long position in the stock based upon technicals by saying:

  • [By Lisa Levin]

    Shares of UniPixel Inc (NASDAQ: UNXL) were down 22 percent to $1.63 after the company announced a public offering of newly issued shares of stock. UniPixel plans to offer 5.35 million shares of its own stock at a public offering price of $1.50 per share with the option for its underwriters to purchase up to an additional 802,500 shares.

  • [By Peter Graham]

    Small cap sensor film stock UniPixel Inc (NASDAQ: UNXL) is sinking by a double digit percentage in after-hours and pre-market trading after reporting Q4 earnings. The problem for UniPixel is that only a few analysts cover the small cap stock and the bottom line loss was a bit worst than the 10 cent loss they were expecting. The stock also had a slight uptick ahead of earnings:

Leave a Reply

Your email address will not be published. Required fields are marked *